Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

124.26 +1.21 (+0.98%)
Streaming Delayed Price Updated: 3:01 PM EDT, May 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S ADR

< Previous 1 2 3 4 5 6 7 8 9
...
43 44 Next >
What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk
Senate Committee probes Novo Nordisk's pricing tactics for diabetes and obesity meds. Sanders demands transparency on pricing, signaling broader industry scrutiny. Medicare coverage expansion could... 
Via Benzinga
3 Biotech Stocks With Skyrocketing Potential: April 2024
These three biotech stocks, with robust fundamentals and long-term prospects represent the sector’s finest at this time. 
Via InvestorPlace
Meet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market
Lilly recently announced news that could solve a big problem. 
Via The Motley Fool
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly. 
Via InvestorPlace
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Good news could be just around the corner for two drugmakers not named Novo Nordisk. 
Via The Motley Fool
Why Novo Nordisk Topped the Market Today
It's not only spending its capital on developing new drugs. 
Via The Motley Fool
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $5,200 Today
Via Benzinga
Better Buy: Pfizer vs. Viking Therapeutics
These two pharma stocks have followed distinct paths of late. Which is the better investment? 
Via The Motley Fool
3 Stocks With the Potential to Surpass Analyst Expectations for 2024
These stocks to buy are set to surpass analyst expectations, with exciting product and service developments sparking unforeseen growth. 
Via InvestorPlace
Changing Frugal Eating Habits - How Novo Nordisk/Eli Lilly's Weight Loss Drugs Reshaping Food Spending
Discover how GLP-1 drugs reshape consumer spending in food industries. Novo Nordisk's Wegvoy and Eli Lilly's Zepbound gain traction, altering dining habits. 
Via Benzinga
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever
These stocks probably won't be getting much cheaper. 
Via The Motley Fool
3 Relatively Safe Growth Stocks You Can Buy and Hold
Low risk and high-reward potential? These stocks could offer both. 
Via The Motley Fool
3 Biotech Stocks Set to Double by 2028
These are three of the top biotech stocks set to double by 2028. Add them to your portfolio to maximize your potential gains. 
Via InvestorPlace
Got $500? 3 Healthcare Stocks to Buy and Hold Forever
Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk. 
Via The Motley Fool
German Authority Gives Go Ahead To Novo Nordisk's Small Bolt On Acquisition As Danish Firm Seeks To Build Heart Drugs Pipeline
Novo Nordisk's acquisition of Cardior Pharmaceuticals clears regulatory hurdles, advancing cardiovascular treatment development with CDR132L. Learn about the promising phase 2 trials and strategic... 
Via Benzinga
Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025
Facing a shortage, GLP-1 weight loss drugs by Eli Lilly & Novo Nordisk struggle to meet demand. Learn about supply issues and efforts to address them, impacting availability till 2025. 
Via Benzinga
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
ResMed stock reversed higher Thursday after an analyst suggested weight-loss drugs could drive CPAP use. 
Via Investor's Business Daily
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
The company published some very good news from the lab, although it wasn't so encouraging for smaller rivals. 
Via The Motley Fool
Powell And The Great Indecision
In today’s presser, Powell basically said what he typically says. Higher for longer but maybe not as risks remain to the economy while inflation is too sticky. 
Via Talk Markets
Topics Economy
Exposures Economy Interest Rates
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
These three biotech stocks are leading the sector higher on upbeat news but is this as good as it gets or do they have more gas in the tank? 
Via InvestorPlace
Buyback Bonanza: The Top 7 ETFs to Profit From Corporate Cash Splurges
Profit from corporate cash splurges with these top ETFs targeting buyback strategies. Unlock potential gains in a volatile market. 
Via InvestorPlace
Topics ETFs
Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead
Healthcare stocks disappointed again last week with the XLV down over 3% and up only 1.65 % YTD, in a continued downtrend since March 28. 
Via Talk Markets
3 Pharma Stocks That Are Money-Printing Machines in 2024
The economy, and pharma industry, are projected to grow massively. You should invest in these top three pharma stocks. 
Via InvestorPlace
Topics Economy
Exposures Economy
Novo Nordisk and Ginkgo Bioworks Are Teaming Up. Here's Why That's Bullish for Both Stocks.
The collaboration could help solve challenges for both businesses. 
Via The Motley Fool
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard S&P 500 ETF? 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund? 
Via The Motley Fool
NYSE:NVO is showing good growth, while it is not too expensive.
For those who appreciate growth without the sticker shock, NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) is worth considering. 
Via Chartmill
Viking Therapeutics: Strong Results In Obesity
With a potential best in class drug for oral and injectable use, Viking Therapeutics has to be on many Big Pharma/Bio acquisition wish lists, as the company represents a very scarce asset in the $100... 
Via Talk Markets
Nvidia Leads 5 Stocks Near Buy Points As S&P 500 Tests Key Level
AI leader Nvidia bucked the S&P 500 downdraft last week. 
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
BMO's coverage of Novo Nordisk, spotlighting its groundbreaking advancements in weight loss and diabetes drugs. Analysts foresee Novo and Eli Lilly maintaining dominance in the obesity market, fueled... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
43 44 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.